ARCUTIS BIOTHERAPEUTICS, INC. financials

ARQT CIK 0001787306

Source: EDGAR filings · Built 2026-06-02T02:21:59Z

Custom taxonomy namespace: ffd

Key metrics by reporting period

Up to six most-recent periods side-by-side. Rows are the curated key lines — revenue, margins, cash, debt, equity, cash-flow totals, plus the derived and valuation metrics we compute on top. For every tag a filer reported in one period, use the single-filing drilldown below.

Derived Metrics

Concept FY 2025FY 2024FY 2023FY 2022FY 2021FY 2020
Free Cash Flow -6.31M -112.30M -247.49M -258.05M -175.62M -113.35M
EBITDA -6.86M -125.84M -239.55M -300.69M -206.07M -136.52M
Working Capital 281.39M 254.81M 283.76M 399.60M 369.45M 270.22M
Net Debt 71.61M 39.25M 117.52M 148.90M -18.89M -60.12M
Gross Margin 90.24% 90.27% 91.63% 79.54%
Operating Margin -3.25% -65.33% -404.49% -8183.04%
Net Margin -4.29% -71.25% -439.79% -8449.76%
Return on Equity (ROE) -8.52% -88.89% -295.65% -148.61% -69.32% -50.14%
Return on Assets (ROA) -3.73% -40.14% -76.79% -69.32% -50.56% -45.49%
Current Ratio 3.17× 4.15× 7.08× 11.57× 12.09× 12.96×
Debt-to-Equity 0.60× 0.70× 2.32× 0.97× 0.26× 0.02×
Cash Conversion Ratio 0.35× 0.80× 0.94× 0.83× 0.85× 0.83×
Accruals Ratio -0.02× -0.08× -0.04× -0.12× -0.08× -0.08×
SBC % of Revenue 10.73% 21.23% 65.12% 886.65%
CapEx Coverage -8.20× -784.32× -577.24× -773.92× -175.50× -352.13×
Free Cash Flow Per Share $-0.05 $-0.93 $-3.57 $-4.69 $-3.55 $-3.18

Valuation Metrics

Concept FY 2025FY 2024FY 2023FY 2022FY 2021FY 2020
P/S 9.52× 8.35× 5.24× 245.08×
P/B 18.90× 10.42× 3.53× 4.31× 3.50× 4.50×

Income Statement

Concept FY 2025FY 2024FY 2023FY 2022FY 2021FY 2020
Revenues 376.07M 196.54M 59.61M 3.69M
Cost of Goods and Services Sold 36.70M 19.13M 4.99M 754.00K 0
Research and Development Expense 77.05M 76.42M 110.58M 182.44M 145.56M 115.31M
Selling, General and Administrative Expense 274.55M 229.39M 185.15M 122.12M 60.97M
Operating Expenses 305.31M 206.53M 136.65M
Operating Income (Loss) -12.23M -128.40M -241.10M -301.63M -206.53M -136.65M
Income Tax Expense (Benefit) 1.17M 647.00K 3.11M 0 0 0
Net Income (Loss) Attributable to Parent -16.14M -140.04M -262.14M -311.46M -206.36M -135.68M
Earnings Per Share, Basic $-0.13 $-1.16 $-3.78 $-5.66 $-4.18 $-3.80
Weighted Average Number of Shares Outstanding, Basic 127.23M 120.96M 69.31M 55.03M 49.41M 35.67M
Earnings Per Share, Diluted $-0.13 $-1.16 $-3.78 $-5.66 $-4.18 $-3.80
Weighted Average Number of Shares Outstanding, Diluted 127.23M 120.96M 69.31M 55.03M 49.41M 35.67M

Balance Sheet

Concept FY 2025FY 2024FY 2023FY 2022FY 2021FY 2020
Cash and Cash Equivalents, at Carrying Value 42.91M 71.33M 88.39M 53.64M 96.45M 65.08M
Assets, Current 411.23M 335.82M 330.43M 437.41M 402.77M 292.83M
Assets 432.97M 348.89M 341.37M 449.27M 408.15M 298.27M
Long-term Debt 108.96M 107.20M 201.80M 197.77M 72.35M 0
Liabilities, Current 129.84M 81.01M 46.67M 37.81M 33.33M 22.60M
Long-term Debt, Excluding Current Maturities 107.96M 107.20M 201.80M 197.77M 72.35M 0
Liabilities 243.49M 191.35M 252.70M 239.69M 110.47M 27.65M
Stockholders' Equity Attributable to Parent 189.48M 157.54M 88.67M 209.58M 297.68M 270.62M
Common Stock, Shares, Outstanding 123.33M 117.85M 96.79M 61.04M 50.26M 43.34M

Cash Flow Statement

Concept FY 2025FY 2024FY 2023FY 2022FY 2021FY 2020
Net Cash Provided by (Used in) Operating Activities -5.63M -112.16M -247.06M -257.71M -174.63M -113.03M
Payments to Acquire Property, Plant, and Equipment 686.00K 143.00K 428.00K 333.00K 995.00K 321.00K
Net Cash Provided by (Used in) Investing Activities -30.25M 28.82M 180.23M -87.20M -75.95M -181.82M
Net Cash Provided by (Used in) Financing Activities 6.97M 66.20M 101.32M 301.80M 281.95M 298.14M

Raw XBRL tagging for a single filing

Every us-gaap and custom concept the filer tagged for one fiscal period, grouped by statement. Start here when a number in the trend table above surprises you and you want to see the exact tag behind it. Derived and valuation rows are omitted here because they already appear in the trend table.

Most recent filing shown by default.

Compare filings side-by-side

Diff any two filings with deltas and added / removed tags.

Immaterial rows are USD line items under 1% of the period's revenue — the noise floor below which a single tag rarely moves the investment thesis. Revenue is read from the filer's top-line concept (Revenues / RevenueFromContractWithCustomerExcludingAssessedTax, with a fallback chain). Non-USD rows, rows without a numeric value, and every row on a filing with no identifiable revenue anchor stay visible. Flip the switch off to see every tag the filer reported for the period.

Loading filing details…

Methodology

All facts on this page come straight from SEC EDGAR XBRL company-facts filings (ARQT CIK 0001787306), grouped by financial statement using FASB's base us-gaap presentation taxonomy. Filers may re-parent concepts onto different statements in their own extension taxonomy, so a handful of rows can show up under a different statement than on the actual 10-K / 10-Q; custom concepts and any we couldn't map fall into Other. Hover a cell to see the fully-qualified concept name and the filer's description.

For the full methodology — statement grouping, the Other bucket, derived metrics, and fact tooltips — see the methodology reference for the statement grouping, the "Other" bucket, derived metrics, and fact tooltips.

Related tickers

SNA

Snap-on Inc

CAMP

CAMP4 Therapeutics Corporation

KLRS

KALARIS THERAPEUTICS, INC.